AstraZeneca PLC

LSE:AZN.L

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 217.40 B

Share Price

USD 140.24

Avg Daily Volume

2,582,257

Change (1 day)

-1.30%

Change (1 year)

-10.63%

Change (YTD)

7.08%

AstraZeneca PLC EBITDA for the year ending December 31, 2024: USD 15.44 B

AstraZeneca PLC EBITDA is USD 15.44 B for the year ending December 31, 2024, a 10.97% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

AstraZeneca PLC EBITDA for the year ending December 31, 2023 was USD 13.91 B, a 53.13% change year over year.
AstraZeneca PLC EBITDA for the year ending December 31, 2022 was USD 9.09 B, a 77.68% change year over year.
AstraZeneca PLC EBITDA for the year ending December 31, 2021 was USD 5.11 B, a -36.75% change year over year.
AstraZeneca PLC EBITDA for the year ending December 31, 2020 was USD 8.08 B, a 20.44% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

LSE: AZN.L

AstraZeneca PLC

CEO	Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
IPO Date	May 21, 1993
Location	United Kingdom
Headquarters	1 Francis Crick Avenue
Employees	94,300
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.